



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 04/21/2022 17:40  
**Last Report Issued** 01/14/2019 06:54

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 2504SP-POS  
**Patient ID** 2504SP-POS  
**Chain** 19000128  
**DOB** Not Given  
**Sex** Not Given  
**Workorder** 19000128  
**Received** 01/14/2019

**Lab ID** 19000128-001  
**Matrix** Serum or Plasma  
**Patient Name** 2504SP-POS  
**Patient ID** 2504SP-POS  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** Not frozen as required

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**2504SP Levodopa, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

Levodopa	5.0	mcg/mL	0.020	
----------	-----	--------	-------	--

The target plasma concentration of levodopa in Parkinsonian patients is 2 +/- 0.5 mcg/mL. The average peak plasma levodopa concentration following a single oral dose of Sinemet® containing 200 mg levodopa was 1.2 mcg/mL at 0.5 hours for normal release and 3.3 mcg/mL at 2 hours for controlled release. At steady-state, the average trough plasma levodopa concentration following oral Sinemet® containing 200 mg levodopa was 0.07 mcg/mL for normal release and 0.16 mcg/mL for controlled release.

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.